[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100644680":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":20,"collaborators":10,"id":24,"slug":25,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":29,"acronym":10,"eligibilityCriteria":30,"healthyVolunteers":26,"sex":31,"minAge":32,"maxAge":10,"enrollmentInfo":33,"targetDuration":36,"studyType":37,"phases":10,"briefSummary":38,"conditions":39,"keywords":43,"overallStatus":49,"whyStopped":10,"lastUpdateSubmitDate":50,"lastUpdatePostDateStruct":51,"startDateStruct":54,"completionDateStruct":56,"leadSponsor":58,"locationsCount":10},{"fullName":5,"class":6},"Zhejiang Cancer Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Recurrent metastatic cervical cancer with complete response",null,"Patients with recurrent and metastatic cervical cancer who achieved complete response after standard first-line systemic therapy.",[13],"Diagnostic Test: Biospecimen collection (peripheral blood and paraffin tumor tissue)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Biospecimen collection (peripheral blood and paraffin tumor tissue)","Longitudinal collection of peripheral blood plasma at scheduled time points and collection of archived paraffin-embedded recurrent tumor tissue sections for ctDNA and HPV cfDNA quantitative detection, HPV genotyping and gene variation analysis.",[9],{"type":21,"investigatorFullName":22,"investigatorTitle":23,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Tao Zhu","Professor","100644680","circulating-cfdna-and-hpv-as-prognostic-biomarkers-for-first-line-recurrent-metastatic-cervical-cancer-100644680",false,"NCT07673211","Circulating cfDNA and HPV as Prognostic Biomarkers for First-Line Recurrent Metastatic Cervical Cancer","A Prognostic Research on First-Line Recurrent and Metastatic Cervical Cancer Using Circulating Cell-Free DNA and Human Papillomavirus Detection","Inclusion Criteria:\n\n1. Histopathologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma;\n2. Patients with first recurrent or metastatic cervical cancer (including primary stage IVB disease);\n3. Received standard first-line therapy (TP\u002FTC regimen plus immunotherapy ± bevacizumab);\n4. Achieved complete response (CR) following standard first-line treatment;\n5. Archived pathological biopsy specimens of recurrent\u002Fmetastatic lesions prior to treatment available in our hospital;\n6. Participated in clinical trials of pharmaceutical therapy for first-line recurrent\u002Fmetastatic cervical cancer conducted at our institution;\n7. Voluntarily participates in this study and provides written informed consent;\n8. Agrees to serial peripheral blood collection at scheduled time points;\n9. Willing to complete scheduled follow-up visits;\n10. Aged ≥ 18 years old.\n\nExclusion Criteria:\n\n1. History of other malignant tumors within the past 2 years;\n2. Pregnant or breastfeeding women;\n3. Severe concomitant diseases, including: cardiovascular diseases (e.g., uncontrolled heart failure, unstable angina, etc.); pulmonary diseases (e.g., severe chronic obstructive pulmonary disease, interstitial pneumonia and other conditions impairing respiratory function); hepatic and renal dysfunction (e.g., decompensated liver cirrhosis, severe renal failure requiring dialysis, etc.);\n4. Refusal to sign informed consent;\n5. Refusal to undergo serial blood collection.","FEMALE","18 Years",{"count":34,"type":35},60,"ESTIMATED","3 Years","OBSERVATIONAL","Primary Objective of this study: To investigate the correlation between longitudinal quantitative dynamics of circulating tumor DNA (ctDNA) and HPV-derived cell-free DNA (HPV cfDNA) in peripheral blood and clinical prognosis among patients with recurrent and metastatic cervical cancer who achieved complete response following standard first-line systemic therapy.",[40,41,42],"Cervical Cancer","Recurrent Cervical Cancer","Metastatic Cervical Cancer",[44,45,46,47,48],"Cervical cancer","ctDNA","HPV cfDNA","Complete response","Prognosis","NOT_YET_RECRUITING","2026-06-23",{"date":52,"type":53},"2026-06-29","ACTUAL",{"date":55,"type":35},"2026-06",{"date":57,"type":35},"2029-12",{"name":5,"class":6}]